专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2015177058A1 LIQUID PHARMACEUTICAL COMPOSITION 审中-公开
标题翻译：液体药用组合物
公开(公告)号：WO2015177058A1
公开(公告)日：2015-11-26
申请号：PCT/EP2015/060817
申请日：2015-05-15
申请人： ARES TRADING S.A.
发明人： RINALDI, Gianluca , FRATARCANGELI, Silvia , DEL RIO, Alessandra
IPC分类号： A61K9/00 , A61K38/00 , A61K47/18 , A61K47/26
CPC分类号： A61K39/39591 , A61K9/0019 , A61K47/183 , A61K47/26 , C07K16/241 , C07K2317/21 , C07K2317/76
摘要： The present invention relates to novel liquid pharmaceutical compositions of adalimumab, which include adalimumab or a biosimilar thereof, an histidine buffering agent such as histidine (or histidine buffer system such as histidine/imidiazolium-histidine), and a sugar stabiliser such as trehalose. Such a combination of components furnishes formulations having a stability (e.g. on storage and when exposed to stress) which is comparable to or an improvement upon those known in the art, and with fewer ingredients. Such advances will help adalimumab treatments to become more widely available at lower cost, and prolong the viability of pre-loaded delivery devices (e.g. pre-filled syringes) to reduce unnecessary waste of the drug.
摘要翻译：本发明涉及阿达木单抗的新型液体药物组合物，其包括阿达木单抗或其生物相似物，组氨酸缓冲剂如组氨酸（或组氨酸缓冲体系如组氨酸/亚氨基唑 - 组氨酸）和糖稳定剂如海藻糖。这种组合组合物提供了具有稳定性（例如在储存和暴露于应力时）的制剂，其与本领域已知的那些相当或改善，并且具有较少的成分。这些进展将有助于阿达木单抗治疗以更低的成本变得更广泛地使用，并且延长预加载递送装置（例如预装注射器）的生存能力，以减少不必要的药物浪费。

2. 发明申请

WO2016124588A1 LIQUID PHARMACEUTICAL COMPOSITION 审中-公开
标题翻译：液体药用组合物
公开(公告)号：WO2016124588A1
公开(公告)日：2016-08-11
申请号：PCT/EP2016/052170
申请日：2016-02-02
申请人： ARES TRADING S.A.
发明人： RINALDI, Gianluca , FRATARCANGELI, Silvia , DEL RIO, Alessandra
IPC分类号： A61K9/00 , A61K47/26 , A61K47/32 , A61K9/08 , A61K47/08
CPC分类号： A61K47/32 , A61K9/0019 , A61K9/08 , A61K47/08 , A61K47/26
摘要： The present invention relates to novel liquid pharmaceutical compositions of adalimumab, which include adalimumab or a biosimilar thereof, and at least one component selected from the group consisting of: a polyvinylpyrrolidone (PVP) surfactant, an inositol sugar stabiliser, and a gluconate salt toncifier. Such a combination of components furnishes formulations having a stability (e.g. on storage and when exposed to stress) which is comparable to or an improvement upon those known in the art, and with fewer ingredients. Such advances will help adalimumab treatments to become more widely available at lower cost, and prolong the viability of pre-loaded delivery devices (e.g. pre-filled syringes) to reduce unnecessary waste of the drug.
摘要翻译：本发明涉及阿达木单抗的新型液体药物组合物，其包括阿达木单抗或其生物相似物，以及至少一种选自聚乙烯吡咯烷酮（PVP）表面活性剂，肌醇糖稳定剂和葡萄糖酸盐调味剂的组分。这种组合组合物提供了具有稳定性（例如在储存和暴露于应力时）的制剂，其与本领域已知的那些相当或改善，并且具有较少的成分。这些进展将有助于阿达木单抗治疗以更低的成本变得更广泛地使用，并且延长预加载递送装置（例如预装注射器）的生存能力，以减少不必要的药物浪费。

3. 发明申请

WO2015177059A1 LIQUID PHARMACEUTICAL COMPOSITION 审中-公开
标题翻译：液体药用组合物
公开(公告)号：WO2015177059A1
公开(公告)日：2015-11-26
申请号：PCT/EP2015/060818
申请日：2015-05-15
申请人： ARES TRADING S.A.
发明人： RINALDI, Gianluca , FRATARCANGELI, Silvia , DEL RIO, Alessandra
IPC分类号： A61K9/00
CPC分类号： A61K39/39591 , A61K9/0019 , A61K47/12 , A61K47/26 , C07K16/241 , C07K2317/21 , C07K2317/94
摘要： The present invention relates to novel liquid pharmaceutical compositions of adalimumab, which include adalimumab or a biosimilar thereof, a citrate buffering agent/system such as sodium citrate/citric acid, and a sugar stabiliser such as trehalose. Such a combination of components furnishes formulations having a stability (e.g. on storage and when exposed to stress) which is comparable to or an improvement upon those known in the art, and with fewer ingredients. Such advances will help adalimumab treatments to become more widely available at lower cost, and prolong the viability of pre-loaded delivery devices (e.g. pre-filled syringes) to reduce unnecessary waste of the drug.
摘要翻译：本发明涉及阿达木单抗的新型液体药物组合物，其包括阿达木单抗或其生物相似物，柠檬酸盐缓冲剂/体系如柠檬酸钠/柠檬酸和糖稳定剂如海藻糖。这种组合组合物提供了具有稳定性（例如在储存和暴露于应力时）的制剂，其与本领域已知的那些相当或改善，并且具有较少的成分。这些进展将有助于阿达木单抗治疗以更低的成本变得更广泛地使用，并且延长预加载递送装置（例如预装注射器）的生存能力，以减少不必要的药物浪费。

4. 发明申请

WO2015177057A1 LIQUID PHARMACEUTICAL COMPOSITION 审中-公开
标题翻译：液体药用组合物
公开(公告)号：WO2015177057A1
公开(公告)日：2015-11-26
申请号：PCT/EP2015/060816
申请日：2015-05-15
申请人： ARES TRADING S.A.
发明人： RINALDI, Gianluca , FRATARCANGELI, Silvia , DEL RIO, Alessandra
IPC分类号： A61K9/00 , A61K47/10 , A61K47/26 , A61K9/19 , C07K16/24
CPC分类号： A61K39/39591 , A61K9/0019 , A61K9/19 , A61K47/02 , A61K47/12 , A61K47/26 , A61K2039/505 , A61K2039/54 , C07K16/241 , C07K2317/21 , C07K2317/76
摘要： The present invention relates to novel liquid pharmaceutical compositions of adalimumab, which include adalimumab or a biosimilar thereof, an acetate buffering agent/system such as sodium acetate/acetic acid, and a sugar stabiliser such as trehalose. Such a combination of components furnishes formulations having a stability (e.g. on storage and when exposed to stress) which is comparable to or an improvement upon those known in the art, and with fewer ingredients. Such advances will help adalimumab treatments to become more widely available at lower cost, and prolong the viability of pre-loaded delivery devices (e.g. pre-filled syringes) to reduce unnecessary waste of the drug.
摘要翻译：本发明涉及阿达木单抗的新型液体药物组合物，其包括阿达木单抗或其生物相似物，乙酸盐缓冲剂/体系如乙酸钠/乙酸和糖稳定剂如海藻糖。这种组合组合物提供了具有稳定性（例如在储存和暴露于应力时）的制剂，其与本领域已知的那些相当或者改进，并且具有较少的成分。这些进展将有助于阿达木单抗治疗以更低的成本变得更广泛地使用，并且延长预加载递送装置（例如预装注射器）的生存能力，以减少不必要的药物浪费。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式